1-(4-fluorophenyl)-3-(piperidin-4-yl)-1-propanone | 76000-17-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-fluorophenyl)-3-(piperidin-4-yl)-1-propanone
• 英文别名: 1-(4-fluorophenyl)-3-(piperidin-4-yl)propan-1-one；1-(4-Fluorophenyl)-3-piperidin-4-ylpropan-1-one
• CAS: 76000-17-4
• 化学式: C₁₄H₁₈FNO
• 分子量: 235.301
• InChiKey: KRSZAIJDFCKWMS-UHFFFAOYSA-N

物化性质

• 沸点：
  352.9±12.0 °C(Predicted)
• 密度：
  1.068±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-fluorophenyl)-3-(piperidin-4-yl)-1-propanone 在 sodium hydroxide 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 生成 4-(3-(4-fluorophenyl)-3,3-(ethylenedioxy)propyl)-1-(benzyloxycarbonyl) piperidine
  参考文献：
  名称：

  1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains

  摘要：

  The 4-(3-phenylprop-1-yl)piperidine moiety of the 1,3,4-trisubstituted pyrrolidine CCR5 antagonist 1 was modified with electron deficient aromatics as well as replacement of the benzylic methylene with sulfones, gem-difluoromethylenes and alcohols in an effort to balance the antiviral potency with reasonable pharmacokinetics. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00829-6
• 作为产物：
  描述：

  1-N-BOC-4-哌啶丙酸 在 N-甲基吗啉 、 三氟乙酸 、 氯甲酸异丁酯 作用下， 以 二氯甲烷 为溶剂， 生成 1-(4-fluorophenyl)-3-(piperidin-4-yl)-1-propanone
  参考文献：
  名称：

  1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains

  摘要：

  The 4-(3-phenylprop-1-yl)piperidine moiety of the 1,3,4-trisubstituted pyrrolidine CCR5 antagonist 1 was modified with electron deficient aromatics as well as replacement of the benzylic methylene with sulfones, gem-difluoromethylenes and alcohols in an effort to balance the antiviral potency with reasonable pharmacokinetics. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00829-6

文献信息

• The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression
  作者：Xiaokang Li、Jinwen Li、Yunyuan Huang、Qi Gong、Yan Fu、Yixiang Xu、Junyang Huang、Haolan You、Dong Zhang、Dan Zhang、Fei Mao、Jin Zhu、Huan Wang、Haiyan Zhang、Jian Li

  DOI：10.1016/j.ejmech.2021.114045

  日期：2022.2

  pharmacophores of the antidepressant vilazodone (5-HT1A receptor partial agonist and serotonin transporter inhibitor) and the anti-AD drug donepezil (acetylcholinesterase inhibitor) together to develop a series of multi-target-directed ligands for potential therapy of the comorbidity of AD and depression. Accordingly, 55 vilazodone-donepezil chimeric derivatives were designed and synthesized, and their triple-target

  抑郁症是阿尔茨海默病 (AD) 最常见的共病精神症状之一，迄今为止还没有专门为此目的批准的有效药物。在此，我们提出了一种新的治疗策略，将抗抑郁药维拉佐酮（5-HT 1A受体部分激动剂和5-羟色胺转运蛋白抑制剂）和抗AD药物多奈哌齐（乙酰胆碱酯酶抑制剂）的关键药效​​团结合在一起，开发了一系列多靶点。用于潜在治疗 AD 和抑郁症共病的定向配体。因此，设计并合成了 55 种维拉佐酮-多奈哌齐嵌合衍生物，以及它们对乙酰胆碱酯酶 5-HT 1A的三靶点活性。受体和血清素转运蛋白进行了系统评估。其中，化合物5在体外表现出很强的三靶点生物活性、低hERG钾通道抑制和可接受的脑分布。重要的是，口服 5 mg/kg 的化合物5二盐酸盐可显着减轻小鼠模型的抑郁症状并改善认知功能障碍。简而言之，这些结果突出了维拉佐酮-多奈哌齐嵌合体作为治疗 AD 和抑郁症合并症的前瞻性治疗方法。
• Central Cholinergic Agents. IV. Synthesis and Acetylcholinesterase Inhibitory Activities of .OMEGA.-(N-Ethyl-N-(phenylmethyl)amino)-1-phenyl-1-alkanones and Their Analogues with Partial Conformational Restriction.
  作者：Yuji ISHIHARA、Masaomi MIYAMOTO、Takahiro NAKAYAMA、Giichi GOTO

  DOI：10.1248/cpb.41.529

  日期：——

  Inhibitors of acetylcholinesterase (AChE) have been designed based on a working hypothesis of the enzyme's active site. These compounds were tested for their inhibitory activities on AChE and ω-[N-ethyl-N-(phenylmethyl)amino]-1-phenyl-1-alkanones (3) were found to be potent inhibitors. Various analogues of 3 were prepared to study the effect on AChE inhibition of partial restriction of conformation. Compounds with potent AChE inhibition were further evaluated in terms of central selectivity : the ratio of central action (ameliorationg effect on scopolamine-induced memory impairment using a T-maze alternation task) to peripheral action.

  乙酰胆碱酯酶（AChE）抑制剂的设计是基于酶的活性位点的工作假设。这些化合物被测试了其对AChE的抑制活性，ω-[N-乙基-N-(苯甲基)氨基]-1-苯基-1-烷酮（3）被发现是有效的抑制剂。为了研究构象部分限制对AChE抑制的影响，制备了3的各种类似物。具有强效AChE抑制的化合物进一步评估了其中心选择性：中心作用（在T型迷宫交替任务中改善斯科波拉明诱导的记忆损害的效果）与外周作用的比率。
• US4294841A
  申请人：——

  公开号：US4294841A

  公开（公告）日：1981-10-13